{"id":12252,"date":"2018-12-20T09:15:48","date_gmt":"2018-12-20T14:15:48","guid":{"rendered":"https:\/\/medicarereport.org\/?p=12252"},"modified":"2018-12-20T09:15:48","modified_gmt":"2018-12-20T14:15:48","slug":"why-the-u-s-remains-the-worlds-most-expensive-market-for-biologic-drugs","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=12252","title":{"rendered":"Why The U.S. Remains The World\u2019s Most Expensive Market For \u2018Biologic\u2019 Drugs"},"content":{"rendered":"

(By Sarah Jane Tribble for Kaiser Health News)<\/p>\n

Europeans have found the secret to making some of the world\u2019s costliest medicines much more affordable, as much as 80 percent cheaper than in the U.S.<\/p>\n

Governments in Europe have compelled drugmakers to bend on prices and have thrown open the market for so-called biosimilars, which are cheaper copies of biologic drugs made from living organisms. The brand-name products \u2014 ranging from Humira for rheumatoid arthritis to Avastin for cancer \u2014 are high-priced drugs that account for 40 percent of U.S. pharmaceutical sales.\u00a0 Continue reading article here…<\/a><\/p>\n

Kaiser Health News is a nonprofit national health policy news service that is part of the nonpartisan Henry J. Kaiser Family Foundation.<\/p>\n

\"\"<\/a><\/p>\n

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/pre>\n","protected":false},"excerpt":{"rendered":"
(By Sarah Jane Tribble for Kaiser Health News) Europeans have found the secret to making some of the world\u2019s costliest<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[21,15],"tags":[],"class_list":["post-12252","post","type-post","status-publish","format-standard","hentry","category-health-care-finance","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/12252","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=12252"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/12252\/revisions"}],"predecessor-version":[{"id":12253,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/12252\/revisions\/12253"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=12252"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=12252"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=12252"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}